{"contentid": 488498, "importid": NaN, "name": "Bigger Bristol Myers powers ahead in first quarter", "introduction": "Bristol Myers Squibb matched analysts\u00e2\u0080\u0099 revenue forecasts for the first quarter, reporting $11.1 billion in global sales, and an earnings per share (EPS) figure of $0.89.", "content": "<p>Bristol Myers Squibb (NYSE: BMY) matched analysts&rsquo; revenue forecasts for the first quarter of 2021, reporting $11.1 billion in global sales, and an earnings per share (EPS) figure of $0.89.</p>\n<p>Net income was $4 billion, following Generally Accepted Accounting Principles (GAAP).</p>\n<p>The company was boosted by strong revenues in the USA, increasing 4% to $7 billion, with international revenues up 1% at $4.1 billion.</p>\n<p>Bristol Myers raised its EPS guidance range slightly, to between $3.18 and $3.38 for 2021, with the expectation that worldwide revenues will increase in the high-single digits.</p>\n<p>The firm has performed strongly following its $74 billion acquisition of erstwhile local rival Celgene, beating estimates in the final quarter of 2020 to deliver full-year revenues of $42.5 billion.</p>\n<p>The purchase has given BMS dozens of new early-stage assets as well as a range of candidates to take through late stage trials in the coming period, many of which could hit the market within two years, if all goes well.</p>\n<p>The firm said R&amp;D expenses decreased 6% to $2.2 billion in the first quarter, as the firm moves past asset acquisition charges and other specified items related to the Celgene acquisition.</p>\n<p>On the data and regulatory front, BMS highlighted multiple milestones for Opdivo (nivolumab) and Yervoy (ipilimumab) in the quarter, including positive results from the Phase II/III RELATIVITY-047 study of relatlimab and Opdivo in first-line metastatic or unresectable melanoma.</p>\n<p>Chief executive Giovanni Caforio said: &ldquo;I am proud of our team&rsquo;s hard work and dedication, which led to important milestones with significant potential to benefit patients across multiple disease states.&rdquo;</p>\n<p>He added: &ldquo;These accomplishments, combined with our financial strength and flexibility, further advance our opportunity to renew our portfolio and drive long-term sustainable growth.&rdquo;</p>\n<h2>Selected product performance</h2>\n<p>Revlimid (lenalidomide) - $2.9 billion, up 1% from $2.9 billion.</p>\n<p>Eliquis (apixaban) - $2.9 billion, up 9% from $2.6 billion.</p>\n<p>Opdivo (nivolumab) - $1.72 billion down 3% from $1.76 billion</p>\n<p>Orencia (abatacept) - $758 million up 6% from $714 million.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-04-29 14:26:00", "meta_title": NaN, "meta_keywords": "billion, quarter, Myers, Bristol, revenues, Bigger, powers, global, earnings, sales, matched, Squibb, reporting, forecasts, revenue, share, figure, firm", "meta_description": "Bristol Myers Squibb matched analysts\u00e2\u0080\u0099 revenue forecasts for the first quarter, reporting $11.1 billion in global sales, and an earnings per share (EPS) figure ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-29 14:25:57", "updated": "2021-04-29 15:19:48", "access": NaN, "url": "https://www.thepharmaletter.com/article/bigger-bristol-myers-powers-ahead-in-first-quarter", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bristol_myers_large-1.jpg", "image2id": "bristol_myers_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Autoimmune Disorders, Cardio-vascular, Oncology", "topic_tag": "Financial, Management, Research", "geography_tag": "USA", "company_tag": "Bristol-Myers Squibb", "drug_tag": "Eliquis, Opdivo, Orencia, Revlimid, Yervoy", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-29 14:26:00"}